Brief Description
The ACTION3 Study will examine if the investigational medicine, DMX-200 (repagermanium), reduces the amount of proteinuria (protein in your urine) and slows the decline of kidney function, when taken in addition to a medicine called an angiotensin II receptor blocker (ARB) for 104 weeks.
Estimated Enrollment
22
Estimated End Date
Mid-year 2026
Trial is for people with
Primary FSGS or FSGS of undetermined cause confirmed through a kidney biopsy or documentation of genetic FSGS, diagnosed within 7 ...
Study Goal
The main purpose of this study is to see if DMX-200 (repagermanium) reduces proteinuria and slows the loss of kidney function when ...
What is involved for the patient?
This study is looking at how safe a potential new, investigational medication (DMX-200) is and whether it works for people with a rare ...
About the drug or intervention
The study drug DMX 200 is a medication designed to reduce the function of a protein called C-C chemokine receptor type 2 (CCR2). The ...